Roche’s Alzheimer’s Drug Fails In Phase III Giving Eisai/Biogen A Clear Run
Fails To Produce Significant Slowing Of Disease
Roche’s gantenerumab has failed to make the grade in its GRADUATE studies, leaving the field wide open for Eisai and Biogen’s lecanemab.
